Overview

Population Pharmacokinetics and Pharmacodynamics of Beta-lactams of Interest in Adult Patients From Intensive Care Units

Status:
Unknown status

Trial end date:
2020-10-15

Target enrollment:
0

Participant gender:
All

Summary

Antibiotics are still most often administered on an empiric fashion, as defined for the general population with dosages only adapted based on weight and renal and/or hepatic functions. As a result, serum concentrations show important interpatient variations with the risk of being subtherapeutic or toxic. Recent studies with temocillin, ceftriaxone, or meropenem confirm this for patients in intensive care units. The aim of the study will be to measure the total and free concentrations of temocillin, ceftriaxone, and meropenem in patients hospitalized in Intensive Care Units for pulmonary infections or another infection for which one of the above mentioned antibiotics is indicated. Patients will be stratified according to the level of their renal function. The antibiotics will be assayed in plasma as well as other accessible fluids in order to assess their pharmacokinetic properties.

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Université Catholique de Louvain

Treatments:

Anti-Bacterial Agents
Antibiotics, Antitubercular
beta-Lactams
Ceftriaxone
Lactams
Meropenem
Penicillins
Temocillin
Thienamycins

Criteria

Inclusion Criteria:

- Patients with suspicion or documentation of of an infection requiring intravenous
antibiotic therapy (this includes any patient admitted to the Intensive Care Unit for
an infection (or developing an infection) that calls for administration of temocillin,
ceftriaxone or meropenem).

Exclusion Criteria:

- Patients allergic to β-lactams

- IgE-mediated hypersensibility to penicillins

- any biological abnormality that the attending physician considers as susceptible to
delay or perturb in a significant manner the interpretation of the trial

- lack of accepted informed consent

- patient with therapeutic limitations